Depemokimab for treating chronic rhinosinusitis withnasal polyps


featured image

Depemokimab is in clinical development for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adults.

Interventions: Depemokimab
Indications: Nasal polyps , Rhinosinusitis
Therapeutic Areas: Ear Nose and Throat (ENT)
Year: 2024

Depemokimab is in clinical development for the treatment of chronic rhinosinusitis with nasal
polyps (CRSwNP) in adults. CRSwNP is a combination of two conditions: chronic rhinosinusitis
and nasal polyps. Chronic rhinosinusitis is a condition in which the sinuses (air-filled spaces in the
bones around the nose) are inflamed causing difficulty in breathing due to nasal blockage. Nasal
polyps are painless soft growths inside the nose. Symptoms of CRSwNP include congestion, nasal
discharge, reduced or loss of smell and facial pain or pressure. The exact cause of CRSwNP is
unknown, but allergy, asthma, infection, and aspirin sensitivity have been shown to be associated
with the disease. After treatment with standard of care therapy, many patients still experience
symptoms and sometimes a reoccurrence of nasal polyps thereby posing a therapeutic challenge.